Table of Contents

company-logo

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Oncology Dividend Announcement

• Cullinan Oncology does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Cullinan Oncology dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Cullinan Oncology Dividend History

Cullinan Oncology Dividend Yield

Cullinan Oncology current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Cullinan Oncology stock? Use our calculator to estimate your expected dividend yield:

Cullinan Oncology Financial Ratios

P/E ratio-7.02
PEG ratio-0.07
P/B ratio1.60
ROE-26.54%
Payout ratio0.00%
Current ratio24.46
Quick ratio24.46
Cash Ratio4.22

Cullinan Oncology Dividend FAQ

Does Cullinan Oncology stock pay dividends?
Cullinan Oncology does not currently pay dividends to its shareholders.
Has Cullinan Oncology ever paid a dividend?
No, Cullinan Oncology has no a history of paying dividends to its shareholders. Cullinan Oncology is not known for its dividend payments.
Why doesn't Cullinan Oncology pay dividends?
There are several potential reasons why Cullinan Oncology would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Cullinan Oncology ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Cullinan Oncology has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Cullinan Oncology a dividend aristocrat?
Cullinan Oncology is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Cullinan Oncology a dividend king?
Cullinan Oncology is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Cullinan Oncology a dividend stock?
No, Cullinan Oncology is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Cullinan Oncology stocks?
To buy Cullinan Oncology you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Cullinan Oncology stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.